Abstract 127P
Background
There is no widely used prognostic tool to demonstrate the benefit of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced hepatocellular carcinoma (HCC). We aimed to establish the prognostic score and demonstrate the real-world efficacy of FOLFOX4 in Thai patients.
Methods
Between August 2017 and December 2021, 58 patients with HCC treated with FOLFOX4 were identified. Efficacies of FOLFOX4, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), were assessed. The prognostic score was constructed by stepwise cox proportional hazards regression combined with clinical experience to select variables for the best model.
Results
44 patients (76%) received FOLFOX4 as first-line systemic therapy. The efficacies of FOLFOX4 in the entire cohort were ORR of 8.6% and clinical benefit rate (CBR) of 29.3%. The median OS and PFS were 4.8 and 3.7 months, respectively. Four variables were included in the new prognostic score to predict 6-month overall survival based on their clinical relevance: L, the presence of lung metastasis; A, alcoholic cirrhosis; B, elevated total bilirubin; and S, sorafenib naive. The new prognostic "LABS" score classified all patients into low-, intermediate-, and high-risk groups, demonstrating the median OS of 9.3, 4.2, and 2.1 months, respectively (P<0.0001). The C-index and area under receiver operating characteristic curve of this score were 0.71 and 0.73, respectively.
Conclusions
The FOLFOX4 regimen showed comparable ORR, PFS, and OS efficacy to previous reports. The proposed prognostic “LABS” score clearly discriminated patients who would have the benefit from FOLFOX4. Therefore, we suggest that FOLFOX4 should be considered as one of the options for those who cannot approach immunotherapy and targeted therapy, particularly with a low-risk score. However, this model should be further evaluated in the larger cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - V-set and immunoglobulin domain containing 1 (VSIG1): Gene vs protein expression in colorectal cancer tissue samples
Presenter: Simona Gurzu
Session: Poster viewing 02
58P - Clinicopathologic profile and outcomes of rectal cancer (RC) in the young (<50 years old): A single institution experience
Presenter: Fatma Amina Hussin Ibrahim
Session: Poster viewing 02
59P - Platelet-derived growth factor (PDGF)-CC serum as clinical outcome predictor after six cycles of chemotherapy in colorectal cancer at RSMH Palembang
Presenter: Erty Sundarita
Session: Poster viewing 02
60P - Predictors of survival in stage III colorectal cancer patients treated with surgery and adjuvant chemotherapy: A single institution observational study
Presenter: Keng Man Chiang
Session: Poster viewing 02
61P - Can total neoadjuvant therapy in locally advanced rectal cancer replace standard treatment protocol?
Presenter: Ankita Mallick
Session: Poster viewing 02
62P - Chief complaints and baseline clinicopathological features of patients with colorectal cancer in a tertiary hospital in Yogyakarta Indonesia
Presenter: Yasjudan Putra
Session: Poster viewing 02
63P - Tumor sidedness and clinicopathological features of colorectal cancer in Medical Oncology Department, Yangon General Hospital: A retrospective review
Presenter: Thiri Tun
Session: Poster viewing 02
64P - Clinical profile and treatment outcome of patients with non-metastatic colon cancer: A single institutional study from India
Presenter: Sandip Ganguly
Session: Poster viewing 02
65P - Comparison of survival and recurrence pattern in Thai early stage colorectal cancer patients by tumor sidedness
Presenter: Chanchai Charonpongsuntorn
Session: Poster viewing 02
77P - Long-term outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: The FUGES-012 randomized clinical trial
Presenter: Qing Zhong
Session: Poster viewing 02